Hagop Kantarjian, MD
UT MD Anderson Cancer Center · MD Anderson Cancer Center, Houston, Texas · M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Hagop Kantarjian, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:39 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT01649622 · Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL)M.D. Anderson Cancer Center · withdrawn · Leukemia, Lymphoma · principal investigator
- Ph2NCT01466179 · Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)Amgen Research (Munich) GmbH · completed · Acute Lymphoblastic Leukemia · principal investigator
- Ph2NCT01272245 · Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)M.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- Ph1NCT01139151 · 4'-Thio-araC (Thiarabine) in Advanced Hematologic MalignanciesM.D. Anderson Cancer Center · completed · Leukemia · study chair
- Ph2NCT01134575 · CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)M.D. Anderson Cancer Center · completed · Acute Lymphoblastic Leukemia · study chair
- Ph2NCT00422032 · 2 Arm Study of Clofarabine IV in MDS PatientsM.D. Anderson Cancer Center · completed · Myelodysplastic Syndrome, Leukemia · principal investigator
- Ph2NCT00414310 · Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)M.D. Anderson Cancer Center · completed · Myelodysplastic Syndrome, Acute Myelogenous Leukemia · principal investigator
- Ph2NCT00299156 · Oral Clofarabine Study in Patients With Myelodysplastic SyndromeM.D. Anderson Cancer Center · completed · Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia · principal investigator
- Ph2NCT00113321 · Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine FailureM.D. Anderson Cancer Center · terminated · Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:39 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in childhood acute lymphoblastic leukemia.